HK1167392A1 - Adenosine receptor ligands and uses thereof - Google Patents
Adenosine receptor ligands and uses thereofInfo
- Publication number
- HK1167392A1 HK1167392A1 HK12108064.0A HK12108064A HK1167392A1 HK 1167392 A1 HK1167392 A1 HK 1167392A1 HK 12108064 A HK12108064 A HK 12108064A HK 1167392 A1 HK1167392 A1 HK 1167392A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor ligands
- adenosine receptor
- adenosine
- ligands
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20090360007 EP2210891A1 (en) | 2009-01-26 | 2009-01-26 | New adenosine receptor ligands and uses thereof |
| PCT/IB2010/000416 WO2010084425A1 (en) | 2009-01-26 | 2010-01-25 | New adenosine receptor ligands and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1167392A1 true HK1167392A1 (en) | 2012-11-30 |
Family
ID=40669959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12108064.0A HK1167392A1 (en) | 2009-01-26 | 2012-08-16 | Adenosine receptor ligands and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9029393B2 (pt) |
| EP (2) | EP2210891A1 (pt) |
| JP (2) | JP5680553B2 (pt) |
| CN (1) | CN102365280B (pt) |
| AU (1) | AU2010207494B2 (pt) |
| BR (1) | BRPI1007018B8 (pt) |
| CA (1) | CA2750449C (pt) |
| CY (1) | CY1114329T1 (pt) |
| DK (1) | DK2391625T3 (pt) |
| ES (1) | ES2419280T3 (pt) |
| HK (1) | HK1167392A1 (pt) |
| IL (1) | IL214167A (pt) |
| NZ (1) | NZ594405A (pt) |
| PT (1) | PT2391625E (pt) |
| WO (1) | WO2010084425A1 (pt) |
| ZA (1) | ZA201105791B (pt) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221321B2 (en) | 2002-06-07 | 2012-07-17 | Verathon Inc. | Systems and methods for quantification and classification of fluids in human cavities in ultrasound images |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| US20120220581A1 (en) | 2009-10-30 | 2012-08-30 | Janssen-Cilag, S.A. | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| KR102008946B1 (ko) * | 2010-08-03 | 2019-08-08 | 노브알리스 도이칠란트 게엠베하 | 친화성 크로마토그래피에 의한 항체 및 Fc-융합 단백질 정제용 리간드 |
| GB2497476B (en) * | 2010-09-06 | 2018-01-10 | Guangzhou Inst Biomed & Health | Amide Compounds |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| WO2013033620A1 (en) * | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as pdgfr kinase inhibitors |
| KR20150013435A (ko) | 2012-02-08 | 2015-02-05 | 그라피니티 파머수티컬스 게엠베하 | 친화 크로마토그래피 ＩＶ에 의한 항체 및 Ｆｃ-융합 단백질 정제용 리간드 |
| RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
| CA2875057C (en) | 2012-07-09 | 2021-07-13 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyrazine compounds and their use as inhibitors of the phosphodiesterase 10 enzyme |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| JO3544B1 (ar) * | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
| KR20190078646A (ko) | 2016-11-18 | 2019-07-04 | 머크 샤프 앤드 돔 코포레이션 | 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체 |
| EP3618829B1 (en) * | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| CR20190593A (es) | 2017-06-22 | 2020-05-10 | Novartis Ag | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas |
| JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
| JP2021509009A (ja) | 2017-11-30 | 2021-03-18 | ノバルティス アーゲー | Ｂｃｍａターゲティングキメラ抗原受容体及びその使用 |
| TW202400599A (zh) | 2018-02-27 | 2024-01-01 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及***并嘧啶 |
| IL301295A (en) | 2018-03-14 | 2023-05-01 | Surface Oncology Inc | Antibodies that bind CD39 and uses thereof |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CR20200571A (es) | 2018-06-01 | 2021-01-18 | Novartis Ag | Moléculas de únion contra bcma y usos de las mismas |
| TWI748194B (zh) * | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Ｆｘｒ有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| TW202402759A (zh) | 2018-07-05 | 2024-01-16 | 美商英塞特公司 | 作為a2a/a2b抑制劑之稠合吡嗪衍生物 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3117512A1 (en) | 2018-10-25 | 2020-04-30 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
| JP7473544B2 (ja) | 2018-10-25 | 2024-04-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体 |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
| JP2022524290A (ja) * | 2019-01-31 | 2022-05-02 | 杏林製薬株式会社 | １５－ｐｇｄｈ阻害薬 |
| EP3921319B1 (en) * | 2019-02-07 | 2024-03-06 | BeiGene, Ltd. | Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist |
| WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3124935A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021055329A1 (en) | 2019-09-16 | 2021-03-25 | Surface Oncology, Inc. | Anti-cd39 antibody compositions and methods |
| EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| US20210115127A1 (en) | 2019-09-25 | 2021-04-22 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
| US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン |
| CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| EP4255904A2 (en) * | 2020-12-03 | 2023-10-11 | Domain Therapeutics | Novel par-2 inhibitors |
| GB202019622D0 (en) * | 2020-12-11 | 2021-01-27 | Adorx Therapeutics Ltd | Antagonist compounds |
| JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN115093372B (zh) * | 2022-06-16 | 2023-05-30 | 安徽工程大学 | 一种咪唑衍生物的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2764387B1 (fr) | 1997-06-05 | 1999-07-23 | Centre Nat Rech Scient | Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand |
| US7105550B2 (en) * | 2000-03-01 | 2006-09-12 | Christopher Love | 2,4-disubstituted thiazolyl derivatives |
| JP2005530788A (ja) * | 2002-05-13 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類 |
| US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| EP1673085B1 (en) * | 2003-09-26 | 2011-11-09 | Exelixis, Inc. | C-met modulators and methods of use |
| JP2005126374A (ja) * | 2003-10-24 | 2005-05-19 | Kissei Pharmaceut Co Ltd | 新規なアデノシンａ２ａ受容体拮抗剤 |
| TW200524887A (en) * | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| WO2006068954A2 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2006107784A1 (en) * | 2005-04-05 | 2006-10-12 | Eli Lilly And Company | Imidazopyridazine compounds |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2009060197A1 (en) * | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
| EP2240488B1 (en) * | 2008-02-06 | 2016-11-02 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| CA2755768A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| WO2013033620A1 (en) * | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as pdgfr kinase inhibitors |
| EP2822559B1 (en) * | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
-
2009
- 2009-01-26 EP EP20090360007 patent/EP2210891A1/en not_active Withdrawn
-
2010
- 2010-01-25 PT PT107083735T patent/PT2391625E/pt unknown
- 2010-01-25 CN CN201080013843.5A patent/CN102365280B/zh active Active
- 2010-01-25 EP EP20100708373 patent/EP2391625B1/en active Active
- 2010-01-25 US US13/146,327 patent/US9029393B2/en active Active
- 2010-01-25 CA CA2750449A patent/CA2750449C/en active Active
- 2010-01-25 AU AU2010207494A patent/AU2010207494B2/en active Active
- 2010-01-25 BR BRPI1007018A patent/BRPI1007018B8/pt active IP Right Grant
- 2010-01-25 JP JP2011546998A patent/JP5680553B2/ja active Active
- 2010-01-25 WO PCT/IB2010/000416 patent/WO2010084425A1/en active Application Filing
- 2010-01-25 ES ES10708373T patent/ES2419280T3/es active Active
- 2010-01-25 DK DK10708373T patent/DK2391625T3/da active
- 2010-01-25 NZ NZ59440510A patent/NZ594405A/xx unknown
-
2011
- 2011-07-19 IL IL214167A patent/IL214167A/en active IP Right Grant
- 2011-08-05 ZA ZA2011/05791A patent/ZA201105791B/en unknown
-
2012
- 2012-08-16 HK HK12108064.0A patent/HK1167392A1/xx unknown
-
2013
- 2013-06-19 CY CY20131100498T patent/CY1114329T1/el unknown
-
2015
- 2015-01-06 JP JP2015000660A patent/JP6201098B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2391625B1 (en) | 2013-05-01 |
| ES2419280T3 (es) | 2013-08-20 |
| BRPI1007018B1 (pt) | 2020-03-10 |
| JP5680553B2 (ja) | 2015-03-04 |
| US9029393B2 (en) | 2015-05-12 |
| IL214167A (en) | 2017-09-28 |
| BRPI1007018A2 (pt) | 2016-03-29 |
| CY1114329T1 (el) | 2016-08-31 |
| AU2010207494B2 (en) | 2015-12-03 |
| NZ594405A (en) | 2013-09-27 |
| IL214167A0 (en) | 2011-08-31 |
| ZA201105791B (en) | 2014-01-29 |
| WO2010084425A1 (en) | 2010-07-29 |
| CN102365280B (zh) | 2014-10-29 |
| DK2391625T3 (da) | 2013-07-01 |
| CA2750449A1 (en) | 2010-07-29 |
| JP2012515759A (ja) | 2012-07-12 |
| CN102365280A (zh) | 2012-02-29 |
| BRPI1007018B8 (pt) | 2021-05-25 |
| EP2391625A1 (en) | 2011-12-07 |
| US20110288074A1 (en) | 2011-11-24 |
| JP2015110599A (ja) | 2015-06-18 |
| PT2391625E (pt) | 2013-07-05 |
| EP2210891A1 (en) | 2010-07-28 |
| JP6201098B2 (ja) | 2017-09-27 |
| CA2750449C (en) | 2018-03-13 |
| AU2010207494A1 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1167392A1 (en) | Adenosine receptor ligands and uses thereof | |
| ZA201008829B (en) | Nucleoside cyclicphosphates | |
| AU330004S (en) | Coat | |
| EP2240043A4 (en) | DETACHABLE VEST | |
| EP2430930A4 (en) | TROUSERS FOR THE CORRECTION OF THE SILHOUETTE | |
| GB0810179D0 (en) | Object location | |
| ZA201107486B (en) | Anti-tnf-x antibodies and their uses | |
| EP2494062A4 (en) | ANTI-GLP-1R ANTIBODIES AND THEIR USES | |
| EP2347664A4 (en) | CLOTHING | |
| HK1147977A1 (zh) | 懸掛式座位自動鎖定 | |
| PL2142023T3 (pl) | Ubiór chroniący przed porażeniem prądem elektrycznym | |
| ZA201106705B (en) | Antiviral compounds and uses thereof | |
| HK1167857A1 (en) | Antiviral compounds and uses thereof | |
| HK1195776A1 (zh) | -α 抗-α 抗體及其應用 | |
| ZA201108906B (en) | Clip scoop | |
| IL220536A0 (en) | Anti - bv8 antibodies and uses thereof | |
| IL188336A0 (en) | Garment | |
| EP2353998A4 (en) | PLANE | |
| PL2090199T3 (pl) | Tułów | |
| IL214527A0 (en) | Anti-mst1r antibodies and uses thereof | |
| EP2502627A4 (en) | ANTI CANCER AGENTS | |
| EP2273266A4 (en) | PARASPORIN-1 RECEPTOR AND USE THEREOF | |
| HK1131529A1 (en) | Torso | |
| GB2465336B (en) | Garment | |
| GB2461755B (en) | Garment |